A61K9/4841

METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH AMD3100 AND TACROLIMUS
20220184043 · 2022-06-16 ·

The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34.sup.+ and/or CD133.sup.+ stem cells and a low dose of an immunosuppressive agent.

Dietary supplement
11337986 · 2022-05-24 ·

A method of forming a dietary supplement can include steps of creating a composition of matter comprising tianeptine, CDP Choline, and optionally, Alpha GPC; and providing the composition of matter in a liquid or solid form. The ingredient of tianeptine can be tianeptine sodium, tianeptine free acid, or both. Providing the composition of matter can include filling a container with the composition of matter.

Methods of treating cancer
11351160 · 2022-06-07 · ·

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
20220192991 · 2022-06-23 ·

Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

FORMULATIONS OF LIXIVAPTAN FOR THE TREATMENT OF POLYCYSTIC DISEASE
20220110944 · 2022-04-14 · ·

Formulations of lixivaptan, and methods of using the same, are provided for the treatment of polycystic disease.

PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES
20220096410 · 2022-03-31 ·

The present invention may provide a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method therefor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide.

Methods for treating testicular and ovarian adrenal rest tumors
11304950 · 2022-04-19 · ·

Provided herein are compounds and pharmaceutical compositions for the prevention and treatment of testicular adrenal rest tumors (TART) or ovarian adrenal rest tumors (OART).

MODIFIED PEPTIDE NUCLEIC ACID COMPOSITIONS

The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which can include administration of oligonucleotide analogues that can bind pathogenic nucleotide repeats in DNA or RNA.

Dietary supplement
11318146 · 2022-05-03 ·

A method of forming a dietary supplement can include steps of creating a composition of matter comprising sakae naa and kava; and providing the composition of matter in a liquid or solid form. Providing the composition of matter can include filling a container with the composition of matter.

BETA-HYDROXYBUTYRATE MIXED SALT COMPOSITIONS AND METHODS OF USE
20220110895 · 2022-04-14 ·

Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes and avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts selected from sodium, potassium, calcium, and magnesium salts. The BHB composition may also include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, one or more ketone precursors, supplements, or other compounds that cause a rise in blood ketone levels without adding more electrolytes to the bloodstream, a short-, medium-, or long-chain fatty acid source, vitamins, minerals, flavorants, or other excipients.